The GP 1,2 envelope glycoproteins (GP) of filoviruses (marburg-and ebolaviruses) mediate cell-surface attachment, membrane fusion, and entry into permissive cells. Here we show that a 151-amino acid fragment of the Lake Victoria marburgvirus GP 1 subunit bound filoviruspermissive cell lines more efficiently than full-length GP 1 . An homologous 148-amino acid fragment of the Zaire ebolavirus GP 1 subunit similarly bound the same cell lines more efficiently than a series of longer GP 1 truncation variants. Neither the marburgvirus GP 1 fragment nor that of ebolavirus bound a nonpermissive lymphocyte cell line. Both fragments specifically inhibited replication of infectious Zaire ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Zaire ebolavirus GP 1,2 . These studies identify the receptor-binding domains of both viruses, indicate that these viruses utilize a common receptor, and suggest that a single small molecule or vaccine can be developed to inhibit infection of all filoviruses.
The GP 1,2 envelope glycoproteins (GP) of filoviruses (marburg-and ebolaviruses) mediate cell-surface attachment, membrane fusion, and entry into permissive cells. Here we show that a 151-amino acid fragment of the Lake Victoria marburgvirus GP 1 subunit bound filoviruspermissive cell lines more efficiently than full-length GP 1 . An homologous 148-amino acid fragment of the Zaire ebolavirus GP 1 subunit similarly bound the same cell lines more efficiently than a series of longer GP 1 truncation variants. Neither the marburgvirus GP 1 fragment nor that of ebolavirus bound a nonpermissive lymphocyte cell line. Both fragments specifically inhibited replication of infectious Zaire ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Zaire ebolavirus GP 1,2 . These studies identify the receptor-binding domains of both viruses, indicate that these viruses utilize a common receptor, and suggest that a single small molecule or vaccine can be developed to inhibit infection of all filoviruses.
Filoviruses cause severe hemorrhagic fevers in human and nonhuman primates, with case fatality rates that reach 88%. The family Filoviridae contains two genera, Marburgvirus (species Lake Victoria marburgvirus) and Ebolavirus (species Côte d'Ivoire ebolavirus, Reston ebolavirus, Sudan ebolavirus, and Zaire ebolavirus) (1) . Like all mononegaviruses, filoviruses are enveloped and contain nonsegmented single-stranded RNA genomes of negative polarity (2) .
Filoviral envelope glycoproteins (GP 1,2 ) 3 are type 1 transmembrane and class I viral fusion proteins that mediate cell association, fusion of viral and cellular membranes, and entry of the viral core into the cytosol (3) (4) (5) . The GP 1,2 precursor assembles as a trimer and is modified by N-glycosylation in the endoplasmic reticulum. Trafficking of the trimeric GP 1,2 precursor to the Golgi apparatus leads to refinement of N-glycosylation and addition of O-glycans (6 -9) . Furin-like proteases cleave the polypeptide into the ectodomain GP 1 and the transmembrane GP 2 subunits, both of which remain connected through an intramolecular disulfide bond (GP 1,2 ). Mature GP 1,2 trimers are then incorporated into virions during budding (6, 7, 10) .
The filoviral GP 1 subunit mediates cell-surface receptor binding (8, 11) . Approximately half of the molecular weight of GP 1 is because of Nand O-glycans, many of which are located at the C terminus of the subunit in a region described as the mucin-like domain (12, 13) . This domain contributes to cytopathicity observed in GP 1,2 -expressing cell lines and has been suggested to play a critical role in the pathogenesis of filoviral disease (14 -16) . However, its deletion enhances rather than decreases the efficiency of GP 1,2 -mediated infection (13, 16 -18) . Receptor binding is followed by endocytosis of the virions (19) , acidification of the endocytotic vesicle (4, 5, 20) , and proteolytic processing of GP 1 by endosomal cathepsins (18, 21) . Conformational changes in the filoviral GP 2 subunit facilitate lipid mixing and fusion of the viral and cellular membranes, in a sequence of steps thought similar to those mediated by orthomyxoviral and retroviral transmembrane proteins (22) (23) (24) (25) .
The host cell-surface receptor(s) for filoviruses have not yet been identified (26) . However, the C-type lectin asialoglycoprotein receptor (27, 28) , DC-SIGN (29, 30) , hMGL (31), L-SIGN (29, 30) , and LSECtin (32) , as well as other molecules, including folate receptor-␣ (33) and ␤1 integrins (15) , have been shown or suggested to enhance filovirus cell entry. Subtle differences between marburgvirus and ebolavirus infection efficiencies in different cell lines or following glycosidase or protease treatment have led to the suggestion that these viruses utilize distinct receptors or entry mechanisms (5).
Here we identify fragments of the Lake Victoria marburgvirus (Musoke strain; MARV-Mus) and Zaire ebolavirus (Mayinga stain; ZEBOV-May) GP 1 subunit that efficiently bound cells permissive to filovirus infection but not a nonpermissive lymphocyte cell line. Each fragment inhibited infection of retroviruses pseudotyped with either marburgvirus or ebolavirus GP 1,2 . Both fragments also inhibited replication of infectious Zaire ebolavirus. Our data define homologous regions of otherwise divergent filoviruses that mediate association with a common receptor. Similarities in these receptor-binding domains may provide insight into the nature of this receptor and suggest vaccine and therapeutic approaches effective against all filoviruses. (13) was synthesized based on the ZEBOV-May GP 1,2 protein sequence (GenBank TM accession number NP_066246), using the same strategy. ORFs were ligated into a previously described pCDM8-derived expression vector (35) , encoding the CD5 signal sequence upstream of the ORF insert, and the Fc region of human immunoglobulin G 1 downstream (MARV-Mus GP 1 -(17-432)-Fc and ZEBOV-May GP 1 -(33-308)-Fc). Vectors encoding N-and C-terminal truncation variants were generated by inverse PCR amplification using plasmids encoding MARVMus GP 1 -(17-432)-Fc or ZEBOV-May GP 1 -(33-308)-Fc as templates. An ORF encoding MARV-Mus GP 1,2 residues 17-681 was cloned into a variant of the pCDM8 expression vector encoding the CD5 signal sequence and a C-terminal C9 tag (amino acid sequence GTETSQVAPA) derived from the rhodopsin C terminus (MARV-Mus GP 1,2 ). Plasmid encoding a ZEBOV-May GP 1,2 variant lacking its . sp, signal peptide; tm, transmembrane domain. Cysteine residues, predicted or experimentally confirmed disulfide bonds, and potential N-glycosylation sites are indicated (13, 49) . RBD indicates the truncation variant that most efficiently bound to cell surfaces of filovirus-permissive cells (see Fig. 2 ) and inhibited GP 1,2 -mediated infection (Fig. 4) . B, MARV-Mus GP 1 -Fc, containing GP 1 residues 17-432, fused to the Fc region of human IgG, or truncation variants of GP 1 -Fc, containing the indicated GP 1 residues, were purified from supernatants of transfected 293T cells. GP 1 -Fc and truncation variants were normalized for expression, as shown by Coomassie staining. C, representation of ZEBOV-May GP 1 truncation variants in relation to the full-length ZEBOV-May GP 1,2 envelope glycoprotein (residues 1-676) as in A. D, ZEBOV-May GP 1 -Fc, lacking its mucin-like domain fused to the Fc region of human IgG (33-308-Fc), truncation variants thereof, and control proteins (SARS-CoV RBD-Fc and HIV-1 gp120-Fc) were expressed and normalized as in B.
EXPERIMENTAL PROCEDURES
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mucin-like domain, ZEBOV-May GP 1,2 -(⌬309 -489) (4) , was generously provided by Dr. James Cunningham. Plasmids encoding MARVAng GP 1 -Fc variants were generated by altering their equivalent MARV-Mus GP 1 -Fc variants at codon 74 (T74A), using the QuikChange method (Stratagene). 
Expression of Filovirus Envelope Glycoprotein Variants-For
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and human immunodeficiency virus type 1 (HIV-1) strain ADA gp120-Fc (36, 37)), using the calcium-phosphate method. Cells were washed in Dulbecco's phosphate-buffered saline (Invitrogen) 6 h posttransfection and grown at 37°C in 293 SFM II medium (Invitrogen) supplemented with 100 IU/ml penicillin and 100 g/ml streptomycin, 100 M minimum Eagle's medium nonessential amino acids solution (Invitrogen), 2 mM sodium butyrate (Sigma), and 4 mM L-glutamine (Sigma). Medium was harvested after 48 h, and cell debris was removed by centrifugation and filtration through a 0.22-m pore size filter (Corning Glass). Proteins were precipitated with protein A-Sepharose fast flow beads (Amersham Biosciences) at 4°C for 16 h in the presence of Complete protease inhibitor (Roche Applied Science). Beads were washed once with 30-bed volumes of 0.5 M sodium chloride/phosphatebuffered saline, pH 7.4 (NaCl, Fisher; PBS, Invitrogen), and once with 10-bed volumes of PBS. Proteins were eluted with 50 mM sodium citrate, 50 mM glycine, pH 2 (sodium citrate, Fisher; glycine, Bio-Rad), neutralized with sodium hydroxide (Fisher), dialyzed in PBS, and concentrated with Centricon centrifugal filter units (Millipore). Purified proteins were assayed for size and concentration by comparison to bovine serum albumin standards (Sigma) by SDS-PAGE followed by Bio-Safe Coomassie (Bio-Rad) staining, and by using the Micro BCA protein assay kit (Pierce) according to the manufacturer's instructions.
Cell Binding Assays-293T cells and Vero E6 cells were detached with PBS, 5 mM EDTA (Invitrogen) 48 h after plating, resuspended in an equal volume of PBS, 5 mM MgCl 2 (Sigma), and washed twice in PBS, 2% goat serum (Sigma). Jurkat lymphocytes were harvested and washed twice in PBS, 2% goat serum. GP 1 -Fc constructs, truncation variants thereof, and control proteins were added to 5 ϫ 10 5 cells to a final concentration of 100 nM and incubated on ice for 1.5 h. Cells were washed twice in PBS, 2% goat serum and incubated for 45 min on ice with a 1:40 dilution of goat Fc-specific fluorescein isothiocyanate (FITC)-conjugated anti-human IgG antibody (Sigma) in PBS, 2% goat serum. Cells were washed three times with PBS, 2% goat serum, once in PBS, and fixed with PBS, 2% formaldehyde (Sigma). Cell-surface binding of constructs was detected by flow cytometry with 10,000 events counted per sample. Base-line fluorescence was determined by measuring cells treated only with goat Fc-specific FITC-conjugated anti-human IgG antibody, which was then subtracted from binding values of the tested constructs and control proteins. 
Infection Assay with Filovirus Envelope Glycoprotein-pseudotyped
RESULTS
MARV-Mus GP 1 Truncation Variant 38 -188-Fc Efficiently Binds to
Filovirus-permissive Cells-The envelope glycoproteins of a number of viruses include discrete, independently folded domains that bind cellular receptors as efficiently as their entire ectodomain regions. We sought to identify similar RBDs of MARV-Mus and ZEBOV-May. To determine the location of the MARV-Mus GP 1 RBD, we synthesized a codon-optimized gene encoding the full-length mature MARV-Mus GP 1 protein fused to the Fc region of human immunoglobulin G 1 at the C terminus (17-432-Fc). Four sets of seven truncation variants were created, starting at N-terminal residues 17, 38, 61, or 87 and ending at C-terminal residues 432, 308, 265, 230, 188, 167, or 134 (Fig. 1A) . All 28 constructs expressed efficiently in 293T cells as Fc fusion proteins (Fig.  1B) . Equivalent concentrations of each variant were incubated with MARV-Mus-permissive African green monkey kidney Vero E6 and human embryonic kidney 293T cells and with nonpermissive Jurkat lymphocytes (5), and cell-surface association was determined by 
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flow cytometry (Fig. 2, A-C) . The RBDs of the severe acute respiratory syndrome coronavirus (SARS-CoV) S protein (residues 318 -510) and HIV-1 gp120, expressed as Fc fusion proteins (SARS-CoV RBD-Fc, gp120-Fc), were used as controls (36, 37) . As reported previously, SARS-CoV RBD-Fc efficiently bound SARS-CoV-permissive Vero E6 cells but not 293T cells or Jurkat lymphocytes (40) . Also as expected, gp120-Fc bound CD4-expressing Jurkat lymphocytes but not Vero E6 or 293T cells. All 28 MARV-Mus proteins bound to Vero E6 and 293T cells with varying efficiencies, whereas little or no association was observed with Jurkat lymphocytes in most cases. Successive truncation of the C termini of MARV-Mus GP 1 variants initiated with residues 17, 38, 61, or 87 led to successively increased cell-surface binding to Vero E6 cells, up through the C-terminal truncation at residue 188 ( Fig. 2A) . Further truncation beyond residue 188 decreased cell association. A single exception to this trend was observed with the 87-432-Fc variant, which bound Vero E6 cells with higher affinity than 87-308-Fc and 87-265-Fc. Variants initiated with residues 38, 61, and 87 bound more efficiently than those initiated with residue 17, with MARV-Mus-(38 -188)-Fc consistently binding most efficiently to Vero E6 and 293T cells (Fig. 2B) .
These data identify a cell-binding region of MARV-Mus, located between GP 1 residues 38 and 188.
ZEBOV-May GP 1 Truncation Variant 54 -201-Fc Efficiently Binds to Filovirus-permissive Cells-Deletion of the mucin-like domain has been
demonstrated to markedly increase efficiency of ZEBOV GP 1,2 -mediated infection (13, 16 -18) . To determine the location of the ZEBOVMay GP 1 RBD, we synthesized a codon-optimized gene encoding the mature ZEBOV GP 1 protein, lacking its mucin-like domain, and fused to the IgG1 Fc region . Three sets of four truncation variants were created, starting at N-terminal residues 33, 54, or 76 and ending at C-terminal residues 308, 201, 172, or 156 (Fig. 1C) . With the exception of variant 76 -172-Fc, all variants expressed efficiently (Fig.  1D) . As with the MARV-Mus variants, equivalent concentrations of each variant were incubated with ZEBOV-May-permissive Vero E6 and 293T cells and with nonpermissive Jurkat lymphocytes, and cell association was again assayed by flow cytometry. All 11 ZEBOV-May GP 1 variants bound to Vero E6 and 293T cells, whereas binding to Jurkat lymphocytes was negligible in all cases (Fig. 2, D-F ) . ZEBOV-May GP 1 truncation variants showed a pattern of association to Vero E6 and 293T cells similar to that observed with MARV-Mus variants. In particular, (Fig. 2, D-E (41, 42) . The envelope glycoprotein amino acid sequence of the strain responsible for this outbreak, MARV Angola (MARVAng), is homologous to that of the MARV-Mus strain (43) . In particular, a comparison between MARV-Mus GP 1 amino acid residues 38 -188 with the corresponding region of MARV-Ang yielded only one amino acid change, threonine 74 to alanine (T74A). This alteration was introduced into four MARV-Mus GP 1 truncation variants (MARV-Ang GP 1 -(38 -188)-Fc, -(38 -167)-Fc, -(61-188)-Fc, and -(61-167)-Fc; see Fig. 3A ). Cell association of each of these variants was compared with those of MARV-Mus. Each MARV-Ang variant bound Vero E6 cells slightly less efficiently than its MARV-Mus counterpart (Fig. 3B) . These data largely exclude the possibility that more efficient cellular association of the MARV-Ang cell-binding region contributes to increased severity of disease. (Fig. 4, A-C) . No Fc fusion protein inhibited VSV/ MLV, but both MARV-Mus-(38 -188)-Fc and ZEBOV-May-(54 -201)-Fc efficiently inhibited both MARV/MLV and ZEBOV/MLV. SARS-CoV RBD-Fc did not inhibit infection of either pseudotyped virus. MARV-Mus-(38 -188) was the more potent of the two cellular binding domains, inhibiting MARV/MLV and ZEBOV/MLV with an apparent IC 50 of 50 -100 nM in this assay (Fig. 4A) . These data indicate that MARV-Mus-(38 -188)-Fc and ZEBOV-May-(54 -201)-Fc bind specifically to a common cell-surface factor critical to filovirus entry. Accordingly, and by analogy with other viral entry proteins, we hereafter refer to these cell-binding regions of MARV-Mus and ZEBOV-May GP 1 as RBDs.
Both MARV-Mus and ZEBOV-May GP 1 Cell-binding Regions Inhibit Entry of Retroviruses Pseudotyped with the GP 1,2 of Either Filovirus-To
MARV-Mus-(38 -188)-Fc Inhibits MARV/MLV Entry More Efficiently than
Other GP 1 Truncation Variants-We investigated whether the cellbinding efficiency of MARV-Mus and MARV-Ang GP 1 truncation variants correlated with their ability to inhibit entry of pseudotyped retroviruses (Fig. 5) . Vero E6 cells were incubated with the indicated GP 1 variants together with VSV/MLV or MARV/MLV. None of the GP 1 variants inhibited VSV/MLV entry, whereas most of the MARV-Mus GP 1 variants assayed inhibited that of MARV/MLV (Fig. 5) . Some variation between entry inhibition and cell binding was observed. Notably, full-length MARV-Mus GP 1 -(17-432)-Fc inhibited MARV/MLV entry as efficiently as the defined receptor-binding domains of MARV-Mus and MARV-Ang-(38 -188)-Fc. Apart from this interesting exception, the MARV-Mus RBD inhibited entry more efficiently than any other GP 1 variant assayed (Fig. 5) . We speculate that the mucin-like domain of full-length GP 1 mediates a lower affinity interaction with Vero E6 cells, which may contribute to inhibition of entry but may be more susceptible to the wash steps of the binding assay shown in Fig. 2 . Alternatively, partial misfolding of the longer truncation variants may impair cell surface association. Our data show that variants of the MARV-Mus RBD that are slightly longer or shorter inhibit MARV/MLV less efficiently, consistent with their relatively lower affinity for filovirus-permissive cell lines.
MARV-Mus-(38 -188)-Fc and ZEBOV-May-(54 -201) Inhibit
Replication of Infectious Zaire Ebolavirus-To determine whether the filovirus RBDs also inhibited infectious filovirus, Vero E6 cells were incubated with an infectious Zaire ebolavirus modified to express GFP (39) , at a multiplicity of infection of 1, together with MARV-Mus-(38 -188)-Fc, ZEBOV-May-(54 -201)-Fc, or SARS-CoV RBD-Fc. As expected, viral replication, measured as percentage of infected cells, was specifically inhibited by both filovirus RBDs but not by that of SARS-CoV (Fig.  6 ). Higher concentrations were required to inhibit infectious filovirus than the concentrations used to inhibit pseudotyped retroviruses (Figs. 4 and 6 ). These higher concentrations may be necessary to interfere with the greater number of GP 1,2 molecules present on the filamentous filoviruses, compared with the significantly smaller retroviral pseudotypes. As observed with pseudotyped retroviruses, the MARV-Mus RBD inhibited infectious Zaire ebolavirus more efficiently than the ZEBOV-May RBD (Fig. 6 ). Similar inhibition of Zaire ebolavirus replication was observed in primary monocyte-derived human dendritic cells treated with ZEBOV-May or MARV-Mus RBDs (data not shown). The efficiency with which the MARV-Mus RBD inhibited ebolavirus replication is consistent with the utilization of a common entry factor by both marburg-and ebolaviruses.
DISCUSSION
Enveloped viruses require specific proteins on the virion surface that mediate cell attachment and fusion of the viral and cellular membranes. Viral class I fusion proteins are typically composed of two functionally distinct domains or subunits (44, 45) . The N-terminal domain, GP 1 in the case of filoviruses, mediates cell attachment and receptor associa- tion (8, 11) . Viral entry proteins attach to a number of cell-surface molecules, including glycosaminoglycans and C-type lectins, and these attachments frequently make substantial contributions to the efficiency of viral entry (30, 46 -48) . More critically, most enveloped viruses require one or more cellular receptors to initiate membrane fusion. Receptor-binding regions of viral fusion proteins are typically the most important antibody-neutralizing epitopes on the virion, because of the functional importance of and limited variation in this region (44, 45) . In some cases, such as murine and feline leukemia viruses and SARS coronavirus, the receptor-binding region is localized to a discrete, independently folded domain that can efficiently bind the cellular receptor and inhibit infection (37, 50, 51) . These domains themselves also can be sufficient to elicit protective neutralizing antibodies (45, 52) .
Here we defined small domains of the GP 1 proteins of two divergent filoviruses that bind filovirus-permissive cells. Several lines of evidence suggest that these domains bind a cellular receptor rather than a less specific attachment factor. First, these domains do not associate with a cell line refractory to filovirus infection. Second, they associate with filovirus-permissive cells more efficiently than larger and more heavily glycosylated GP 1 variants. Indeed, ZEBOV-May-(54 -201)-Fc includes no N-glycosylation sites that could associate with a cell-surface lectinlike molecule (MARV-Mus-(38 -188)-Fc has two potential N-glycosylation sites). Third, each domain efficiently inhibits entry mediated by their respective GP 1,2 at 50 -200 nM, indicating that they associate with moderately high affinity and specifically with a factor critical to entry. Finally, they include the most highly conserved region of filovirus GP 1 (17) . The conservation of this region among all marburg-and ebolaviruses raises the possibility that ZEBOV-May-(54 -201)-Fc and MARVMus-(38 -188)-Fc can be used to elicit antibodies that protect against most filoviruses (see Fig. 7 for alignment of the MARV and ZEBOV RBD).
Previous studies of Zaire ebolavirus GP 1,2 are also consistent with association of these domains with a specific cellular receptor. Medina et al. (53) have observed that a Zaire ebolavirus GP 1,2 lacking residues 241-496 nonetheless retained its ability to mediate entry of a pseudotyped retrovirus. (18, 21) .
Although the genomic organization of marburg-and ebolaviruses is similar, and although they cause similar diseases of comparable severity, it has not been clear whether all filoviruses utilize a common receptor. Several observations in the literature raised the possibility that their receptors or entry mechanisms are distinct. Lake Victoria marburgvirus has been reported to be less susceptible than Zaire ebolavirus to treatment of target cells with proteases and glycosidases (5) . Electron micrographs of the virus entering cells have been used to suggest that Lake Victoria marburgvirus enters cells differently than Zaire ebolavirus (54), although earlier work suggests otherwise (19) . Some variation in the relative efficiencies with which Lake Victoria marburg-and Zaire ebo- Filoviruses Use a Common Receptor lavirus GP 1,2 mediated entry in different cell lines also raised the possibility of distinct receptors (5) .
Despite these observations, our data indicate that at least one of the receptors required by each filovirus is common to both. This situation is not unprecedented. For example, SARS coronavirus and human coronavirus NL63 enter cells by distinct mechanisms, although angiotensinconverting enzyme 2 is an obligate receptor for both (55, 56) . Further study will be necessary to clarify whether the downstream entry processes of marburg-and ebolaviruses are similarly distinct.
The conservation of the filovirus receptor-binding domains and their utilization of a common receptor raise the possibility that a vaccine could elicit antibodies that neutralize both marburg-and ebolaviruses, although cross-protective antibodies have not been described to date. Our observations also indicate that small molecules could be designed to inhibit entry of all filoviruses. Such cross-protection would be useful in the rapid containment of a novel filovirus epidemic.
